I just got home and noticed that the first trade today was 315,770 and then no trades for over 6 minutes. Seems a little unusual. But with this stock nothing would totally surprise me. The NCCN lunch symposium on metastatic prostate cancer as a chronic disease paradigm is ending right about now, but I would be shocked if there were any leaks.
Thanks warrior, although the open interest figures for Mar are miniscule, it is plausible that options expiry may have been responsible for some selling of shares and buying out of the money calls. In any case it sucks being committed to a stock so blatantly being manipulated for nickels and dimes.
I can't speak for the nature of the first daily trade, but I would expect little in the way of immediate response to any activities at the NCCN annual meeting. That response will be assimilative, accumulative, and so very gradual as to be imperceptible - unitl we get a compendium listing that suggests a pool of revenue potential beyond MTC. The clinical mojo seems to suggest that Cabo has a niche in many a refractory metastatic setting, and - given a changing treatment landscape - as those unmet needs become manifest, I would expect to see further interest in Cabo's unique anti-angiogenic attributes. I see multiple listings in the compendium as inevitable, given Cabo's undeniable targeted activity despite multiple lines of treatment-induced resistance. The NCCN designated category of utilization will be key to the imbursement process. I believe Ernie pointed out that many payors will cover 2b or better...so anything less will be uneventful in terms of revenue and unlikely to have an impact on PPS.